ArticleResearch square2024
DNA methylation age from peripheral blood predicts progression to Alzheimer's disease, white matter disease burden, and cortical atrophy.
Luke Bonham, Daniel Sirkis, Alina Pang, Leo Sugrue, Hernando Santamaría-García, Agustin Ibanez, Bruce Miller, Jennifer Yokoyama, Michael Corley
Abstract readPreprint
In one paragraphArticle in Research square, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
9 authors.
Luke BonhamDepartment of Radiology and Biomedical Imaging, University of California, San Francisco.
Daniel SirkisMemory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco.
Alina PangDivision of Infectious Diseases, Department of Medicine, Weill Cornell Medicine.
Leo SugrueDepartment of Radiology and Biomedical Imaging, University of California, San Francisco.
Hernando Santamaría-GarcíaPontificia Universidad Javeriana, Physiology and Psychiatry Departments.
Agustin IbanezUniversidad de San Andrés.
Bruce MillerMemory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco.
Jennifer YokoyamaMemory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco.
Michael CorleyDivision of Infectious Diseases, Department of Medicine, Weill Cornell Medicine.
Funding
Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0MTDP-43 Loss-of-Function: Biology to BiomarkersP01AG019724 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Jennifer Merrilees · 2002 to 2026
$67.2MProject 2: Biomarker Analysis, Non-Genetic Risk Factors, and Their Genetic InteractionsU19AG079774 · NIA · UNIVERSITY OF PENNSYLVANIA · PI HELENA Chang CHUI, Gyungah Jun · 2023 to 2026
$39.4MResearch Education ComponentP30AG062422 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Gil Dan Rabinovici · 2019 to 2026
$36.9MTau Metabolism in FTD: From Gene Mutations to Molecular Chaperones and Lysosomal ProteasesU54NS123985 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KARCH, CELESTE MARIE · 2021 to 2025
$9.0MAn automated machine learning approach to language changes in Alzheimer’s disease and frontotemporal dementia across Latino and English-speaking populationsR01AG075775 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MARIA LUISA GORNO TEMPINI, Adolfo Martin Garcia · 2023 to 2026
$7.2MUS-South American Initiative for Genetic-Neural-Behavioral Interactions in Human Neurodegenerative ResearchR01AG057234 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Claudia Duran-Aniotz, Agustin M. Ibanez · 2019 to 2026
$6.1MBiomedical Imaging for Clinician ScientistsT32EB001631 · NIBIB · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI THOMAS M LINK · 2005 to 2026
$5.6MElucidating clinical heterogeneity in early-onset AD via genomics, transcriptomics, and neuroimagingR01AG062588 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI YOKOYAMA, JENNIFER S · 2019 to 2023
$4.0MDecoding epigenetic scars of smoldering neuroinflammation and CNS complications in people with HIVR01MH134391 · NIMH · WEILL MEDICAL COLL OF CORNELL UNIV · PI Michael Jay Corley, Shelli Farhadian · 2023 to 2026
$3.8MSocial epigenetics of Alzheimer's disease and related dementias in Latin American countriesR01AG082056 · NIA · WEILL MEDICAL COLL OF CORNELL UNIV · PI Michael Jay Corley · 2024 to 2026
$3.6MCircadian Disturbance and Dementia in Latin AmericaR01AG083799 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Kun Hu, Agustin M. Ibanez · 2023 to 2026
$3.0MNIA NIH HHS P01 AG019724NIA NIH HHS P30 AG062422NIA NIH HHS R01 AG057234NIA NIH HHS R01 AG062588NIA NIH HHS R01 AG075775NIA NIH HHS R01 AG082056NIA NIH HHS R01 AG083799NIA NIH HHS U01 AG024904NIA NIH HHS U19 AG079774NIBIB NIH HHS T32 EB001631NIDA NIH HHS 75N95022C00031NIMH NIH HHS R01 MH134391NINDS NIH HHS U54 NS123985
6 · The paper itselfAbstract
Cross-sectional studies suggest a limited relationship between accelerated epigenetic aging derived from epigenetic clocks, and Alzheimer's disease (AD) pathophysiology or risk. However, most prior analyses have not utilized longitudinal analyses or whole-brain neuroimaging biomarkers of AD. Herein, we employed longitudinal modeling and structural neuroimaging analyses to test the hypothesis that accelerated epigenetic aging would predict AD progression. Using survival analyses, we found that two second generation epigenetic clocks, DNAmPhenoAge and DNAmGrimAge, predicted progression from cognitively normal aging to mild cognitive impairment or AD and worse longitudinal cognitive outcomes. Epigenetic age was also strongly associated with cortical thinning in AD-relevant regions and white matter disease burden. Thus, in contrast to earlier work suggesting limited applicability of blood-based epigenetic clocks in AD, our novel analytic framework suggests that second-generation epigenetic clocks have broad utility and may represent promising predictors of AD risk and pathophysiology.
Indexed as
DNA methylationepigenetic clockneuroimaging
Identifiers
PMID39574903
PMCPMC11581046
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390